Financials
- Fiscal year
- 2025
- Total assets
- €675,641
- Loss
- -€13,894
- Solvency
- 22.2%
Total assets▼ 5.8%
Net result
20192025
DEVLIES PHARMA
ActiveSummary
DEVLIES PHARMA has been active since 2005 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €149,857 and a net result of -€13,894. Equity remains stable across the filed fiscal years (±0.3% per year). Its solvency ranks better than 33% of 11293 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.7% (low).
Overview
What they do
Retail sale of pharmaceutical products
NACE 47730Warehousing and support activities for transportation NACE 52310
1 site
How big
€675,641total assets 2025
- Staff
- 0.8 FTE
- Equity
- €149,857
- Loss
- -€13,894
Turnover not published (abridged schema)
Who decides
Accounts 47 d early0 of 6 deeds read
Why 50- Higher-failure-rate sector- Annual accounts: weaker financial profile+ Long track recordLatest accounts filed on timeShow the evidence
Checked score
Score 2025
Axes · tick = 2024
Profitability38▼-12
Solvency47▼-1
Growth32▼-46
Track record100
Bankruptcy probability, 12 months
0.7%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €7,000 at 30 days acceptable
Liquidity tight (current ratio 1.01 against 0.96 in 2024; short-term debt: 48.9% and cash: 4% of total assets), and 77.8% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Four signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Retail trade (NACE 47)
about 45% more bankruptcies
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
22.2%
Return on assets
-2.1%
Age of the figures
15 mo
neutral · Latest accounts filed on time
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 15-12-2025, 47 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
47 d early
2024
32 d early
2023
44 d early
2022
32 d early
2021
41 d early
2020
31 d early
2019
46 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 39 days before the deadline; the sector median for financial year 2024 is on the deadline day, and 47% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 30-06-2026 and is due by 31-01-2027. Nothing is late today. Usually files around 21 December (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsPosition in the running window
30-06-2026 close02-10-2026 today31-01-2027 deadline
- Annual accounts filedfiscal year 2025 · abbreviated…
- Weakest financial yearnet -€13,894
- Annual accounts filedfiscal year 2024 · abbreviated…
Key points
By topic
Timeline
- Events
- 12
- Since
- 2016
- Next accounts
- by 31-01-2027
- 15-12-2025Annual accounts filed
- 30-06-2025Weakest financial year
- 30-12-2024Annual accounts filed
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Founded
- 09-12-2005
- Year ends
- 30-06
- Peppol
- Reachable for e-invoices
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.